Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (RHHVF)
OTHER OTC:RHHVF
RHHVF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$269.80 - $354.19
Previous CloseN/A
Volume301.00
Average Volume (3M)4.57K
Market Cap
$257.43B
Enterprise Value$232.87B
Total Cash (Recent Filing)$17.32B
Total Debt (Recent Filing)$36.35B
Price to Earnings (P/E)23.1
Beta0.42
Next Earnings
Jan 29, 2026EPS Estimate
11.39Last Dividend Ex-Date
Mar 27, 2025Dividend Yield3.48%
Share Statistics
EPS (TTM)13.61
Shares Outstanding702,562,700
10 Day Avg. Volume2,423
30 Day Avg. Volume4,574
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)6.41
Price to Sales (P/S)3.26
P/FCF Ratio13.50
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue3.79
Enterprise Value/Gross Profit5.12
Enterprise Value/Ebitda14.11
Forecast
1Y Price Target
$346.44Price Target Upside9.37% Upside
Rating ConsensusHold
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Investment And ExpansionRoche announced a $50 billion investment in the US for Pharma and diagnostics over the next five years, including research and development sites and new manufacturing facilities.
Market ShareRoche continues to take market share in the US across various indications with increasing percentages.
Pharmaceutical SalesKey drivers of the Pharma sales beat include Hemlibra, Xolair, and Actemra, which were ahead by 12%, 19%, and 14% respectively.
Bears Say
Diagnostics PerformancePerformance in diagnostics was weaker than expected with a 4% miss.
Earnings Growth OutlookThe mid-term earnings growth outlook for Roche is projected at 4%, which is lower compared to sector peers at 8%.
Sales GrowthA more challenging US market for Vabysmo drives FY25 sales growth closer to 18% YoY, compared to the pre-Q1 consensus of around 33% growth.
Roche Holding AG News
RHHVF FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was $269.80 and its highest was $354.19 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $257.43B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jan 29, 2026 which is in 176 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 24, 2025. The company reported $13.611 earnings per share for the quarter, beating the consensus estimate of $13.231 by $0.381.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of $11.012 which represents an annual dividend yield of 3.48%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 11.39.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of $13.611 in its last earnings report, beating expectations of $13.231. Following the earnings report the stock price went up 1.338%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in RHHVF
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
RHHVF Company Deck
RHHVF Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in the Pharma segment, with significant growth in sales, profit, and key product performance. However, the Diagnostics segment faced challenges due to the China healthcare pricing reforms, and there were some mixed clinical trial results and safety concerns impacting specific treatments. Overall, the highlights in Pharma and financial management outweighed the challenges, resulting in a generally positive outlook, despite certain areas requiring attention.View all RHHVF earnings summariesRHHVF Stock 12 Month Forecast
Average Price Target
$346.44
▲(9.37% Upside)
Technical Analysis
Ownership Overview
―
Insiders
10.50% Mutual Funds
0.04% Other Institutional Investors
77.16% Public Companies and Individual Investors
Options Prices
Currently, No data available
---